Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. (Q45418238)

From Wikidata

Jump to navigation Jump to search

scientific article published on 20 March 2006

Language	Label	Description	Also known as
English	Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects.	scientific article published on 20 March 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16581161%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16581161%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16581161%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Christa Firbas

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16581161%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Bernd Jilma

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16581161%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Vera Buerger

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16581161%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Sandra Jelovcan

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16581161%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Karen Lingnau

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16581161%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Michael Buschle

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16581161%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Jürgen Frisch

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16581161%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Christoph S Klade

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16581161%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

language of work or name

0 references

publication date

20 March 2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16581161%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16581161%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16581161%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16581161%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

4343-4353

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16581161%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Epidemiology of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Correlation between virus genotype and chronicity rate in acute hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Cell-mediated immunity and the outcome of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

The role of hepatitis C virus specific CD4+ T lymphocytes in acute and chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Analysis of a successful immune response against hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Analysis of successful immune responses in persons infected with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

HCV Persistence and Immune Evasion in the Absence of Memory T Cell Help

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Kinetics of CD4+ and CD8+ Memory T-Cell Responses during Hepatitis C Virus Rechallenge of Previously Recovered Chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Comprehensive Analysis of CD8+-T-Cell Responses against Hepatitis C Virus Reveals Multiple Unpredicted Specificities

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Broad Specificity of Virus-Specific CD4+ T-Helper-Cell Responses in Resolved Hepatitis C Virus Infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Sustained Dysfunction of Antiviral CD8+ T Lymphocytes after Infection with Hepatitis C Virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Hepatitis C virus mutation affects proteasomal epitope processing

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

CD8 Epitope Escape and Reversion in Acute HCV Infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Escape mutations alter proteasome processing of major histocompatibility complex class I-restricted epitopes in persistent hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Immune evasion versus recovery after acute hepatitis C virus infection from a shared source

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Cellular immune selection with hepatitis C virus persistence in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Subversion of effector CD8+ T cell differentiation in acute hepatitis C virus infection: exploring the immunological mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Subversion of effector CD8+ T cell differentiation in acute hepatitis C virus infection: the role of the virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Hepatitis C virus: molecular biology and genetic variability

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Genetic Heterogeneity of Hepatitis C Virus: Quasispecies and Genotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Transloading of tumor antigen-derived peptides into antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Cell-free tumor antigen peptide-based cancer vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Induction of specific immune responses by polycation-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Rapid effector function in CD8+ memory T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Protamine-reactive natural IgM antibodies in human sera. Characterization of the epitope demonstrates specificity of antigenic recognition; occurrence indicates obscurity of origin and function

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

DNA vaccine strategies for hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Perspectives: towards a peptide-based vaccine against hepatitis C virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

The challenge of developing a vaccine against hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Peptide-based vaccines for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.009

7 January 2021

Identifiers

10.1016/J.VACCINE.2006.03.009

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16581161%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16581161%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45418238&oldid=1540330010"